CP
BCYC

Castleview Partners’s Bicycle Therapeutics BCYC Stock Holding History

Castleview Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,704
Closed -$258 – 737
2021
Q4 		$258 Buy
+15,704
New +$866K ﹤0.01% 624
2021
Q2 		$8K Buy
+253
New +$7.64K ﹤0.01% 732

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Castleview Partners's BCYC Position: Q1 2022 in Review

Castleview Partners sold out of Bicycle Therapeutics (BCYC) in Q1 2022, closing a stake of 15,704 shares — an estimated $258 sold.

Castleview Partners first reported a position in BCYC in Q2 2021 and held it in 2 quarters. The position peaked at $8K in Q2 2021. 105 funds tracked by Wall St. Rank hold BCYC as of Q1 2022.

  • Castleview Partners reported no remaining Bicycle Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Castleview Partners sold 15,704 Bicycle Therapeutics shares in Q1 2022, an estimated $258.
  • Castleview Partners first reported a position in Bicycle Therapeutics in Q2 2021 and held it in 2 quarters.
  • Castleview Partners's Bicycle Therapeutics position peaked at $8K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2022.

Based on Castleview Partners's 13F filing for Q1 2022, filed 16 May 2022.